Drugs / Nuvastatic
Nuvastatic
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04552600 | Sep 2019 → Aug 2022 | diabetic retinopathy | Natureceuticals Sdn Bhd | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07669454 | Oct 2025 → Oct 2026 expected | colon carcinoma | Natureceuticals Sdn Bhd | Recruiting | No outcome recorded |
| Phase 3 | NCT07669467 | Oct 2025 → Oct 2026 expected | breast cancer | Natureceuticals Sdn Bhd | Recruiting | No outcome recorded |
| Phase 3 | NCT07669519 | Aug 2025 → Mar 2027 expected | colon carcinoma | Natureceuticals Sdn Bhd | Recruiting | No outcome recorded |
| Phase 3 | NCT07669506 | Jun 2025 → Apr 2026 | breast cancer | Natureceuticals Sdn Bhd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04542447 Comparator | Sep 2020 | COVID-19 | Natureceuticals Sdn Bhd | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nuvastatic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07669454 ↗ |
| Known as | Extract of Orthosiphon Stamineus | “Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA)” NCT07669506 ↗ |
| Known as | NuvastaticTM-C5OSEW5050ESA | “Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA)” NCT07669506 ↗ |
| Action | Inhibit | “extract was found to specifically inhibit VEGF expression and VEGFR phosphorylation” NCT04552600 ↗ |
| Route | Oral | “will be given orally” NCT04552600 ↗ |